We can safely delay excising in situ and early-stage melanomas while managing our patients’ care, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
We can safely delay excising in situ and early-stage melanomas while managing our patients’ care, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
Transcript
How has the management of patients with advanced skin cancers changed from before the pandemic?
The pandemic has changed how we look at skin cancer. And I think one of the main things that's happened, especially in the realm of melanoma, is that we'd normally be very concerned with early-stage melanoma, about getting the cancer out very quickly. But the pandemic has taught us that, and this is also reflected in the more recent [National Comprehensive Cancer Network] guidelines for care, with early-stage melanomas, the re-excision of a known melanoma that's either in situ or considered to be early stage—less than 0.8 mm in Breslow thickness—can be delayed up to 90 days without detriment or [with] minimal effect on the patient's overall outcome. So that's something that's changed how we feel.
We've also had to do a lot of telemedicine discussion and sort of diagnosis over telemedicine, which has been more difficult, I think, for skin cancer patients to have something shown to us over Zoom or something like that. It's not as easy as seeing, of course, that lesion in the office.
Those things, I think, are the main consideration.
But I think the main change will be more with a melanoma, that we now sort of have that understanding that excision in 90 days or less of an early-stage melanoma will not affect the outcome of the patient very much at all.
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More